Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Outcomes of alloSCT following blinatumomab in children and young adults with R/R B-ALL

Mattia Algeri • 15 Apr 2024
EBMT 2024
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T

Mattia Algeri, MD, Bambino Gesù Children’s Hospital, Rome, Italy, discusses a study investigating outcomes for pediatric patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) who receive allogeneic stem cell transplantation (alloSCT) following blinatumomab. The study revealed favorable outcomes in measurable residual disease (MRD) and disease-free survival (DFS). Importantly, subsequent therapy with anti-CD9 CAR T-cells was effective in patients who relapsed following alloSCT. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Vertex: Advisory Board.

More from Mattia Algeri

2:14
The influence of graft source and composition on GvHD
Mattia Algeri • 15 Apr 2024
2:02
Novel approaches for the treatment of GvHD in children: ruxolitinib and tissue regeneration
Mattia Algeri • 15 Apr 2024
2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024

Related Videos

2:05
CAR T-cell therapy programs to improve access for patients with leukemia in Mexico
Alberto Olaya-Vargas • 15 Apr 2024
14:43
Current research into post-alloSCT maintenance therapy in AML
Ali Bazarbachi • 3 May 2024
5:20
Targeted therapies in AML: menin, FLT3 and IDH inhibitors
Felicitas Thol • 19 Apr 2024
4:15
Using MRD to guide post-alloSCT treatment decisions in AML
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals